Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
You can find out more from the FSRH GLP-1 Agonists and Contraception Patient Information Leaflet
This is not treatment failureit reflects successful metabolic recalibration
doi: 10.1016/j.cellimm.2016.08.002 105 FagonePSriburiRWard-ChapmanCFrankMWangJGunterCet al
Jepsen MM, Christensen MB
Improved Blood Sugar Control: These shots can also help regulate blood sugar levels, making them a valuable tool for individuals with diabetes
US$ 25.92
US$ 22.61
US$ 21.65
US$ 20.44
US$ 24.50
US$ 28.50
US$ 26.09
US$ 25.20
US$ 29.88
US$ 28.92
US$ 27.31
US$ 28.55
US$ 26.34
US$ 29.90
US$ 27.94
US$ 28.73
US$ 25.48
US$ 22.82
